EVEROLIMUS VIATRIS 5 mg TABLETS

Introduction

Package Leaflet: Information for the Patient

Everolimus Viatris 5 mg Tablets EFG

Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.

• Keep this package leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
• If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.

Package Leaflet Contents

1. What is Everolimus Viatris and what is it used for
2. What you need to know before taking Everolimus Viatris
3. How to take Everolimus Viatris
4. Possible side effects
5. Storage of Everolimus Viatris
6. Package Contents and Additional Information

1. What is Everolimus Viatris and what is it used for

Everolimus is a cancer medication that contains the active substance everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.

Everolimus is used to treat adult patients with:

• Advanced breast cancer with positive hormonal receptor in postmenopausal women, in whom other treatments (called "non-steroidal aromatase inhibitors") can no longer keep the disease under control. It is administered along with a type of medication called exemestane, a steroidal aromatase inhibitor, used for hormonal treatment of cancer.
• Advanced tumors called neuroendocrine tumors that originate in the stomach, intestine, lung, or pancreas. It is administered if the tumors are not operable and do not produce excess specific hormones or other related natural substances.
• Advanced kidney cancer (advanced renal cell carcinoma), when other treatments (called anti-VEGF treatment) have not helped to stop the disease.

2. What you need to know before taking Everolimus Viatris

Everolimus will only be prescribed to you by a doctor with experience in cancer treatment. Follow your doctor's instructions carefully. They may be different from the general information contained in this package leaflet. If you have questions about everolimus or why you have been prescribed this medication, ask your doctor.

Do not take Everolimus Viatris:

• If you are allergicto everolimus, to related substances such as sirolimus or temserolimus, or to any of the other components of this medication (listed in section 6).

If you think you may be allergic, consult your doctor.

Warnings and Precautions

Consult your doctor before starting to take Everolimus Viatris:

• If you have liver problems or if you have had a disease that may have affected your liver. In this case, your doctor may prescribe a different dose of everolimus.
• If you have diabetes (high blood sugar). Everolimus may increase blood sugar levels and worsen diabetes mellitus. This may require treatment with insulin and/or oral antidiabetic medications. Inform your doctor if you notice excessive thirst or need to urinate more frequently.
• If you need to receive a vaccine while taking everolimus.
• If you have high cholesterol. Everolimus may increase cholesterol and/or other blood fats.
• If you have recently undergone major surgery or if you still have an unhealed wound after surgery. Everolimus may increase the risk of wound healing problems.
• If you have an infection. It may be necessary to treat your infection before starting treatment with everolimus.
• If you have previously suffered from hepatitis B, as it may reactivate during treatment with everolimus (see section 4 "Possible side effects").
• If you have received or are about to receive radiation therapy.

Everolimus may also:

• Weaken your immune system. Therefore, you may be at risk of infection while taking everolimus. If you have a fever or other signs of infection, consult your doctor. Some infections can be severe and have fatal consequences.

Affect kidney function. Therefore, your doctor will monitor your kidney function while you are taking everolimus.

• Cause difficulty breathing, cough, and fever.
• Cause the appearance of ulcers and sores in the mouth. Your doctor may need to interrupt or discontinue treatment with Everolimus Viatris. You may need treatment with a mouthwash, gel, or other products. Some mouthwashes and gels can worsen ulcers, so do not try any without consulting your doctor first. Your doctor may restart treatment with Everolimus Viatris at the same dose or a lower dose.
• Cause radiation therapy complications. Severe radiation therapy complications (such as difficulty breathing, nausea, diarrhea, skin rash, and mouth, gum, and throat pain), including fatal cases, have been observed in some patients taking everolimus at the same time as receiving radiation therapy or taking everolimus shortly after receiving radiation therapy. Radiation recall syndrome (presenting with skin redness or lung inflammation at the site of previous radiation therapy) has also been reported in patients who had received radiation therapy in the past.

Tell your doctor if you are scheduled to receive radiation therapy soon or if you have received radiation therapy in the past.

Tell your doctorif you experience these symptoms.

During treatment, you will undergo periodic blood tests. These tests will determine the number of cells in the blood (white blood cells, red blood cells, and platelets) to check if everolimus is having an unwanted effect on these cells. You will also undergo blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are performed because they may be affected by treatment with everolimus.

Children and Adolescents

Everolimus should not be administered to children or adolescents (under 18 years of age).

Other Medications and Everolimus Viatris

Everolimus may affect how other medications work. If you are taking other medications at the same time as everolimus, your doctor may change the dose of everolimus or the other medications.

Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.

The following may increase the risk of side effects with everolimus:

• Ketoconazole, itraconazole, voriconazole, or fluconazole, and other antifungal medications used to treat fungal infections.

The following may reduce the effectiveness of everolimus:

• Rifampicin, used to treat tuberculosis (TB).
• Efavirenz or nevirapine, used to treat HIV/AIDS.
• St. John's Wort (Hypericum perforatum), a herbal product used to treat depression and other conditions.
• Dexamethasone, a corticosteroid used to treat a wide range of conditions, including inflammatory or immune system problems.
• Phenytoin, carbamazepine, or phenobarbital, and other antiepileptics used to control seizures.

Use of these medications should be avoided during treatment with everolimus. If you are taking any of them, your doctor may prescribe a different medication or change your dose of everolimus.

Taking Everolimus Viatris with Food and Drinks

Do not take grapefruit or grapefruit juice while taking everolimus. It may increase the amount of everolimus in the blood, possibly to a harmful level.

Pregnancy, Breastfeeding, and Fertility

Pregnancy

Everolimus may harm the fetus and is not recommended during pregnancy. Tell your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medication during pregnancy.

Women who can become pregnant must use a highly effective contraceptive method during treatment and up to 8 weeks after finishing treatment. If, despite these measures, you think you may be pregnant, consult your doctor beforetaking more everolimus.

Breastfeeding

Everolimus may harm the breastfed baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Tell your doctor if you are breastfeeding.

Female Fertility

In some patients treated with everolimus, absence of menstrual periods (amenorrhea) has been observed.

Everolimus may affect female fertility. Tell your doctor if you want to have children.

Male Fertility

Everolimus may affect male fertility. Consult your doctor if you want to be a father.

Driving and Using Machines

If you feel abnormally tired (fatigue is a very common side effect), be especially careful when driving or using machines.

Everolimus Viatris contains Lactose

Everolimus Viatris contains lactose (milk sugar). If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.

3. How to take Everolimus Viatris

Follow your doctor's or pharmacist's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.

The recommended dose is 10 mg, once a day. Your doctor will tell you how many everolimus tablets to take.

If you have liver problems, your doctor may start treatment with a lower dose of everolimus (2.5, 5, or 7.5 mg per day).

If you experience side effects while taking everolimus (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period or permanently.

Take everolimus once a day, at about the same time, always with food or always without food.

Swallow the tablet(s) whole with a glass of water. Do not chew or crush the tablets.

If you take more Everolimus Viatris than you should

• If you have taken too much everolimus, or if someone has taken your tablets accidentally, consult your doctor or go to the hospital immediately. Urgent treatment may be necessary.
• Take the package and this package leaflet with you so the doctor knows what you have taken.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (Tel. 91 562 04 20) indicating the medication and the amount ingested.

If you forget to take Everolimus Viatris

If you have missed a dose, take the next dose at the scheduled time. Do not take a double dose to make up for missed doses.

If you stop taking Everolimus Viatris

Do not stop taking everolimus unless your doctor tells you to.

If you have any other questions about using this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

DISCONTINUE treatment with everolimus and seek immediate medical attention if you experience any of the following signs of an allergic reaction:

• Difficulty breathing or swallowing
• Swelling of the face, lips, tongue, or throat

• Severe skin itching, with red-colored rash or bumps on the skin.

The serious adverse effects of everolimus include:

Very Common(may affect more than 1 in 10 people)

• Increased temperature, chills (signs of infection).
• Fever, cough, difficulty breathing, wheezing (signs of lung inflammation, also known as pneumonitis).

Common(may affect up to 1 in 10 people)

• Excessive thirst, high urine output, increased appetite with weight loss, fatigue (signs of diabetes).
• Bleeding (hemorrhage), for example, in the intestinal wall.
• Significant decrease in urine output (sign of renal failure).

Uncommon(may affect up to 1 in 100 people)

• Fever, skin rash, joint pain and inflammation, as well as fatigue, loss of appetite, nausea, jaundice (yellowish skin color), pain in the upper right abdomen, pale stools, dark urine (may be signs of hepatitis B reactivation).
• Shortness of breath, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure).
• Swelling and/or pain in one of the legs, usually in the calf, redness or warmth of the skin in the affected area (signs of blockage of a blood vessel (vein) in the legs caused by a blood clot).
• Sudden onset of breathing problems, chest pain or coughing up blood (potential signs of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked).

potentially of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked).

• Significant decrease in urine output, swelling in the legs, feeling of confusion, back pain (signs of sudden renal failure).
• Rash, itching, acne, difficulty breathing or swallowing, dizziness (signs of a severe allergic reaction, also known as hypersensitivity).

Rare(may affect up to 1 in 1,000 people)

• Difficulty breathing or rapid breathing (signs of respiratory distress syndrome).

If you experience any of these adverse effects, inform your doctor immediately, as they could have fatal consequences.

Other possible adverse effects of everolimus include:

Very Common(may affect more than 1 in 10 people)

• Fatigue, difficulty breathing, dizziness, pale skin, signs of low red blood cell count (anemia).

Common(may affect up to 1 in 10 people)

• Spontaneous bleeding or bruising (signs of low platelet count, also known as thrombocytopenia).
• Fever, sore throat, mouth ulcers due to infections (signs of low white blood cell count, leucopenia, lymphopenia, and/or neutropenia).
• Lymphedema (swelling of body tissues, usually in the arms or legs).
• Difficulty breathing (dyspnea).
• Thirst, low urine output, dark urine, dry reddened skin, irritability (signs of dehydration).
• Sleeping problems (insomnia).
• Headache, dizziness (sign of high blood pressure, also known as hypertension).
• Fever.
• Inflammation of the mucous membrane inside the mouth, stomach, intestine.
• Dry mouth.
• Heartburn (dyspepsia).
• Vomiting.
• Difficulty swallowing (dysphagia).
• Abdominal pain.
• Acne.
• Rash and pain on the palms of the hands or soles of the feet (palmar-plantar syndrome).
• Redness of the skin (erythema).
• Joint pain.
• Mouth pain.
• Menstrual disturbances such as irregular periods.
• High level of lipids (fats) in the blood (hyperlipidemia, increased triglycerides).
• Low potassium level in the blood (hypokalemia).
• Low phosphate level in the blood (hypophosphatemia).
• Low calcium level in the blood (hypocalcemia).
• Dry skin, skin peeling, skin lesions.
• Nail alterations, nail breakage.
• Mild hair loss.
• Abnormal liver function tests (increased alanine and aspartate aminotransferase).
• Abnormal kidney function tests (increased creatinine).
• Eyelid swelling.
• Protein in the urine.

Uncommon(may affect up to 1 in 100 people)

• Weakness, spontaneous bleeding or bruising, and frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (signs of low blood cell count, also known as pancytopenia).
• Lack of taste (ageusia).
• Coughing up blood (hemoptysis).
• Menstrual disturbances such as absence of periods (amenorrhea).
• Frequent urination during the day.
• Chest pain.
• Abnormal wound healing.
• Hot flashes.
• Itchy, red, and watery eyes (conjunctivitis).

Rare(may affect up to 1 in 1,000 people)

• Fatigue, difficulty breathing, dizziness, pale skin (signs of low red blood cell count, possibly due to a type of anemia called pure red cell aplasia).
• Swelling of the face, around the eyes, mouth, and inner mouth and/or throat mucosa, as well as the tongue and difficulty breathing or swallowing (also known as angioedema), may be signs of an allergic reaction.

Frequency Not Known(frequency cannot be estimated from the available data)

• Reaction at the site of previous radiation therapy (e.g., skin redness or lung inflammation) (called radiation recall syndrome).
• Worsening of radiation therapy adverse effects.

If these adverse reactions worsen, inform your doctor and/or pharmacist. Most adverse effects are mild to moderate and usually disappear if treatment is discontinued for a few days.

Reporting of Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Everolimus Viatris

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date stated on the packaging and on the blister after CAD. The expiration date is the last day of the month indicated.

Store in the original packaging to protect it from light.

This medicine does not require special temperature storage conditions.

Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Everolimus Viatris

• The active ingredient is everolimus. Each tablet contains 5 mg of everolimus.
• The other ingredients are butylhydroxytoluene (E-321), hypromellose (E-464), lactose, lactose monohydrate, crospovidone (E-1202), and magnesium stearate (E-470b). See section 2: Everolimus Viatris contains lactose.

Appearance of Everolimus Viatris and Package Contents

Everolimus Viatris are biconvex, oval, white or almost white tablets with "E9VS 5" engraved on one side.

Everolimus Viatris is supplied in blister packs containing 30 or 90 tablets, or packs containing 30 tablets in single-dose perforated blisters.

Not all pack sizes may be marketed.

Marketing Authorization Holder

Viatris Limited

Damastown Industrial Park

Mulhuddart, Dublin 15

Dublin

Ireland

Manufacturer

Synthon Hispania S.L.

Castelló 1

Polígono Las Salinas

08830 Sant Boi de Llobregat

Spain

Or

Synthon BV

Microweg 22

6545 CM Nijmegen

Netherlands

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Viatris Pharmaceuticals, S.L.

C/ General Aranaz, 86

28027 - Madrid

Spain

This medicine is authorized in the Member States of the European Economic Areaand in the United Kingdom (Northern Ireland)with the following names:

GermanyEverolimus Mylan 5 mg Tabletten

BulgariaEverolimus Viatris 5 mg tablets

CroatiaEverolimus Viatris 5 mg tablete

DenmarkEverolimus Viatris, 5 mg tabletter

SpainEverolimus Viatris 5 mg comprimidos EFG

FinlandEverolimus Viatris, 5 mg tabletti

FranceEverolimus Mylan 5 mg comprimés

ItalyEverolimus Mylan 5 mg compresse

NorwayEverolimus Viatris, 5 mg tabletter

NetherlandsEverolimus Viatris 5 mg, tabletten

PortugalEverolimus Mylan

United Kingdom(Northern Ireland)Everolimus Mylan 5 mg tablets

SwedenEverolimus Viatris, 5 mg tabletter

Date of the last revision of this prospectus: December 2022

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) https://www.aemps.gob.es/